FOLH1 and neoplasm: The far lower urinary tracer excretion of [18F]-F-PSMA-1007 may lead to superiority against [68Ga]-Ga-PSMA-11 [24] and renally excreted PSMA tracers in general [25] in terms of evaluation of local tumor recurrence and, possibly, in primary tumor detection.